Analysis by Dr. Joseph MercolaFact Checked July 18, 2022Download PDF
Story at-a-glance
- The COVID-19 pandemic has been a real boon to Pfizer. Not only has it doubled Pfizer’s annual revenue, it has also given the drugmaker unique weight in determining U.S. health policy — something that concerns even staunch vaccine-pushers like Dr. Paul Offit
- Pfizer’s revenue in 2021 was $81.3 billion — approximately double that of 2020 — and the COVID shot accounted for $36.78 billion of that
- Pfizer’s COVID jab dominates 70% of the U.S. and European markets, and Paxlovid, its COVID drug, has become a standard treatment choice in hospitals. This despite findings showing the shot doesn’t prevent infection or transmission, and that Paxlovid causes severe rebound and supercharges mutations
- The U.S. had thrown away 82.2 million expired COVID jab doses as of mid-May 2022, yet the Biden administration ordered another 105 million doses at the end of June 2022 for a fall booster campaign that will cost taxpayers $3.2 billion
- Pfizer’s contracts are almost exclusively slanted in Pfizer’s favor. They’re guaranteed payment while having no financial liability for injuries and deaths, and it appears this indemnification applies even if they were to be found guilty of fraud
According to Kaiser Health News (KHN),1 the COVID-19 pandemic has been a real boon to Pfizer. Not only has it yielded “outsize benefits” in terms of profits, but it has also “given the drugmaker unusual weight in determining U.S. health policy.”
“Based on internal research, the company’s executives have frequently announced the next stage in the fight against the pandemic before government officials have had time to study the issue, annoying many experts in the medical field and leaving some patients unsure whom to trust,” KHN reporter Arthur Allen writes, adding:2
“When last year Bourla suggested that a booster shot would soon be needed, U.S. public health officials later followed, giving the impression that Pfizer was calling the tune.
Some public health experts and scientists worry these decisions were hasty, noting, for example, that although boosters with the mRNA shots produced by Moderna and Pfizer-BioNTech improve antibody protection initially, it generally doesn’t last.
Since January, Bourla has been saying that U.S. adults will probably all need annual booster shots, and senior FDA officials have indicated since April that they agree … The company’s power worries some vaccinologists, who see its growing influence in a realm of medical decision-making traditionally led by independent experts …
When President Biden in September 2021 offered boosters to Americans — not long after [Pfizer CEO Albert] Bourla had recommended them — Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia … wondered, ‘Where’s the evidence you are at risk of serious disease when confronted with COVID if you are vaccinated and under 50?’
Policies on booster recommendations for different groups are complex and shifting, Offit said, but the CDC, rather than Bourla and Pfizer, should be making them. ‘We’re being pushed along,’ he said. ‘The pharmaceutical companies are acting like public health agencies.’”
The fact that a vaccine-pusher like Offit — infamous for claiming a baby can safely tolerate 10,000 vaccines at once3 — is questioning and pushing back against Pfizer’s influence over health policy reveals just how brazen, unethical and potentially dangerous that is.
Massive Profits Made From Useless Products
According to Allen, Pfizer’s revenue in 2021 was $81.3 billion4 — approximately double that of 2020 — and the COVID shot accounted for $36.78 billion5 of that. For comparison, Lipitor, Pfizer’s previous top selling statin, generates roughly $2 billion a year,6 while their strep vaccine, Prevnar 13 rakes in $6 billion a year.7
Its mRNA gene transfer injection against COVID now dominates 70% of the U.S. and European markets, and Paxlovid, Pfizer’s COVID drug, has become a standard treatment choice in hospitals. This, despite researchers finding Paxlovid (molnupiravir) causes severe rebound and supercharges mutations.
In a rational scenario, that finding would have put a stop to its use, but no. In an official health advisory8 to the public, issued May 24, 2022, the U.S. Centers for Disease Control and Prevention first warns that Paxlovid is associated with “recurrence of COVID-19 or ‘COVID-19 rebound,’” and then in the very next sentence stresses in bold print a narrative supporting its use and enriching Pfizer with instructions saying:
“Paxlovid continues to be recommended for early- stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease.”
Allen also notes that, during an investor call, a Pfizer official highlighted reports of Paxlovid’s failure, but spun it into “good news” for investors, as patients may require multiple courses!9 Obviously the objective has long ago shifted from helping humans to raping them for as much profit as possible.
Similarly, while Pfizer’s COVID jab clearly doesn’t prevent infection or spread, and Americans are rejecting the shots in growing numbers — 82.2 million doses had expired and were chucked in the trash as of mid-May 202210 — the U.S. government still went ahead and ordered another 105 million doses at the end of June 2022.
These are intended for a fall booster campaign, at a cost to taxpayers of $3.2 billion.11 The U.S. is actually paying about 50% more for each of these new jab boosters this time around — $30.47 per dose compared to $19.50 per dose paid for the first 100 million doses.
Continue reading “Pfizer’s Pandemic Profits – $81.3 billion in 2021 -Massive Profits From Useless Products –”
